Cizzle Biotechnology Ltd - London-based biotechnology firm - Signs agreement with medical charity St George Street Capital to deliver treatments to patients. The memorandum of understanding signed covers a collaboration to develop a "companion diagnostic platform for certain therapeutic assets" which aims to address clinical needs in autoimmune disease.
A companion diagnostic is a medical device which provides information that is essential for the safe use of a corresponding drug.
As part of the agreement, St George will pay milestone payments to Cizzle of up to GBP1 million and is responsible for providing clinical samples and patients along with providing regulatory advice. Cizzle will use its existing technology covering companion diagnostics to develop the platform, it says.
"We are delighted to have signed the memorandum of understanding with St George," says Cizzle Executive Chair Allan Syms.
"The proposed commercial agreement with them will leverage the technology and know-how of Cizzle Biotechnology into a new area, bringing Cizzle Biotechnology's diagnostic capabilities into the therapeutic arena and broadening the opportunities and potential revenue streams for the company."
Cizzle Biotechnology is a spin-out from the University of York, founded in 2006, and has previously been focused on patent protected technology for the early detection of lung cancer through the development of a blood test for the CIZ1B biomarker.
As part of the memorandum of understanding, St George has granted Cizzle potential future royalty payments of up to £5 million, plus further potential payments from the use of the companion diagnostic.
Current stock price: 5.77 pence
Year-to-date change: down 38% from 9.38p listing price in May
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.